This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Sinha, G. Nat. Biotechnol. 29, 473 (2011).
Editorial. Nat. Biotechnol. 29, 551 (2011).
Abbott, A. Nature 468, 158–159 (2010).
Matheis, K.J. et al. Drug Discov. Today (in press).
Obiol-Pardo, C., Gomis-Tena, J., Ferran Sanz, F., Saiz, F. & Pastor, M. J. Chem. Inf. Model. 51, 483–492 (2011).
S.C. is with Novartis, R.D. is with UCB, P.H.A. is with Lundbeck and C.I. is with Genzyme.
Correspondence should be addressed to Michel Goldman, Executive Director, Innovative Medicines Initiative (IMI), Brussels, Belgium. e-mail: email@example.com
Rights and permissions
About this article
Cite this article
Strohmeier, R., Draghia-Akli, R., Rys, A. et al. IMI moves forward. Nat Biotechnol 29, 689–690 (2011). https://doi.org/10.1038/nbt.1944
This article is cited by
Doctor’s aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center
European Journal of Clinical Pharmacology (2021)